Catalent (CTLT) Given a $45.00 Price Target by Royal Bank of Canada Analysts

Royal Bank of Canada set a $45.00 price target on Catalent (NYSE:CTLT) in a report issued on Friday. The firm currently has a buy rating on the stock.

Other equities analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. boosted their price target on shares of Catalent from $50.00 to $55.00 and gave the company an overweight rating in a research report on Wednesday, August 29th. ValuEngine cut shares of Catalent from a buy rating to a hold rating in a research report on Tuesday, November 6th. Zacks Investment Research cut shares of Catalent from a buy rating to a hold rating in a research report on Thursday, July 26th. Robert W. Baird assumed coverage on shares of Catalent in a research report on Thursday. They set an outperform rating on the stock. Finally, TheStreet cut shares of Catalent from a b- rating to a c+ rating in a research report on Wednesday, November 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $48.22.

Shares of NYSE CTLT traded up $0.34 during midday trading on Friday, hitting $39.39. 845,630 shares of the company traded hands, compared to its average volume of 1,059,771. Catalent has a 12-month low of $34.24 and a 12-month high of $47.87. The company has a debt-to-equity ratio of 1.44, a current ratio of 2.05 and a quick ratio of 1.61. The stock has a market capitalization of $5.51 billion, a P/E ratio of 24.77, a P/E/G ratio of 2.36 and a beta of 1.45.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 6th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.04. Catalent had a net margin of 2.65% and a return on equity of 19.13%. The company had revenue of $551.80 million for the quarter, compared to analysts’ expectations of $582.44 million. During the same quarter in the previous year, the company earned $0.21 earnings per share. Catalent’s quarterly revenue was up 1.5% on a year-over-year basis. Research analysts anticipate that Catalent will post 1.64 earnings per share for the current year.

In other Catalent news, insider John R. Chiminski sold 130,545 shares of the company’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $45.32, for a total value of $5,916,299.40. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Lance Miyamoto sold 6,525 shares of the company’s stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $42.50, for a total transaction of $277,312.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 184,335 shares of company stock worth $8,161,727. Corporate insiders own 1.40% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Nordea Investment Management AB grew its holdings in shares of Catalent by 36.0% during the third quarter. Nordea Investment Management AB now owns 109,694 shares of the company’s stock valued at $4,997,000 after buying an additional 29,008 shares during the last quarter. TIAA CREF Investment Management LLC grew its holdings in shares of Catalent by 82.4% during the third quarter. TIAA CREF Investment Management LLC now owns 729,734 shares of the company’s stock valued at $33,239,000 after buying an additional 329,560 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Catalent by 234.5% during the third quarter. AQR Capital Management LLC now owns 82,106 shares of the company’s stock valued at $3,740,000 after buying an additional 57,562 shares during the last quarter. Macquarie Group Ltd. grew its holdings in shares of Catalent by 4.3% during the third quarter. Macquarie Group Ltd. now owns 2,450,425 shares of the company’s stock valued at $111,617,000 after buying an additional 101,366 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its holdings in shares of Catalent by 5.2% during the third quarter. Thrivent Financial for Lutherans now owns 789,594 shares of the company’s stock valued at $35,966,000 after buying an additional 39,355 shares during the last quarter. Institutional investors and hedge funds own 90.11% of the company’s stock.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Featured Article: Stop Order

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply